Jenburkt Pharmaceuticals Ltd (JENBURPH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 134395, "name": "Jenburkt Pharma", "stock_name": "Jenburkt Pharma", "full_name": "Jenburkt Pharmaceuticals Ltd", "name_url": "stocks-analysis/jenburkt-pharma", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "978.00", "chg": -14.2, "chgp": "-1.43%", "dir": -1, "prev_price": "992.20", "mcapval": "438.00 Cr", "mcap": "Micro Cap", "scripcode": 524731, "symbol": "JENBURPH", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE354A01013", "curr_date": "Sep 18, 03:30 PM", "curr_time": "04:29 AM", "last_traded_at": "Sep 18, 03:30 PM IST", "bse_nse_vol": "386 ", "exc_status": "Active", "traded_date": "Sep 18, 2026", "traded_date_str": "2026 09 18", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jenburkt-pharma-134395-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Jenburkt Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-4191105", "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/JenburktPharmac_mojoScore_4191105.png", "date": "2026-09-12 10:10:14", "description": "Jenburkt Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 7 August 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 12 September 2026, providing investors with the latest comprehensive analysis." }, { "title": "Jenburkt Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-4173397", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/JenburktPharmac_mojoScore_4173397.png", "date": "2026-08-28 10:10:23", "description": "Jenburkt Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 August 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Jenburkt Pharmaceuticals Ltd Forms Death Cross Signalling Bearish Trend", "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-forms-death-cross-signalling-bearish-trend-4168989", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/JenburktPharmac_dealthcross_4168989.png", "date": "2026-08-25 13:26:02", "description": "Jenburkt Pharmaceuticals Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s near-term prospects amid ongoing sector challenges." }, { "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-4157871", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/JenburktPharmac_mojoScore_4157871.png", "date": "2026-08-17 10:10:20", "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 7 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 August 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Jenburkt Pharmaceuticals Declines 1.34% Amid Mixed Signals and Margin Pressures", "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-declines-134-amid-mixed-signals-and-margin-pressures-4144295", "imagepath": "", "date": "2026-08-09 16:00:06", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>3 Aug:</strong> Stock opens strong at Rs.1,090.75 (+1.29%) amid positive market sentiment</p>\n <p><strong>5 Aug:</strong> Sharp 5.64% rally to Rs.1,162.05 signalling bullish momentum</p>\n <p><strong>6 Aug:</strong> Mixed technical signals emerge despite price volatility</p>\n <p><strong>7 Aug:</strong> Quarterly results reveal margin pressures; stock falls 6.44% to Rs.1,062.50</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,076.90</div></div>\n <div class=\"stat-item\"><div class=\"..." }, { "title": "Jenburkt Pharmaceuticals Reports Decline in Quarterly Financial Performance Amid Margin Pressures", "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-reports-decline-in-quarterly-financial-performance-amid-margin-pressures-4141831", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/JenburktPharmac_fintrenddot_4141831.png", "date": "2026-08-07 11:00:07", "description": "Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable reversal in its recent financial trajectory. The company’s latest quarterly results for June 2026 reveal a marked decline in key performance metrics, signalling a shift from previously positive trends to a more challenging operating environment." }, { "title": "Jenburkt Pharmaceuticals Ltd. is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-hold-by-marketsmojo-4139589", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/JenburktPharmac_mojoScore_4139589.png", "date": "2026-08-06 10:11:57", "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 August 2026, providing investors with an up-to-date perspective on the company’s performance and outlook." }, { "title": "Jenburkt Pharmaceuticals Ltd. Exhibits Shift to Mildly Bullish Momentum Amid Mixed Technical Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-exhibits-shift-to-mildly-bullish-momentum-amid-mixed-technical-signals-4138965", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/JenburktPharmac_technicaldot_4138965.png", "date": "2026-08-06 08:00:14", "description": "Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a nuanced picture of the stock’s near-term prospects." }, { "title": "Jenburkt Pharmaceuticals Ltd.: Valuation Shift Signals Changing Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-valuation-shift-signals-changing-market-sentiment-4138953", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/JenburktPharmac_valuationdot_4138953.png", "date": "2026-08-06 08:00:10", "description": "Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, prompting a downgrade in its Mojo Grade from Buy to Hold. This change reflects evolving market perceptions as the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios move into more expensive territory compared to historical and peer benchmarks." } ], "total": 537, "sid": "134395", "stock_news_url": "https://www.marketsmojo.com/news/jenburkt-pharmaceuticals-134395" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Change in Management", "datetime": "04-Sep-2026", "details": "Pursuant to Regulation 30 Read with Schedule III of the SEBI(Listing Obligations and Disclosure Requirnments ) Regulations 2015 we hereby inform you about the change in Senior Manaaement personnel of the Company.", "source": "BSE" }, { "caption": "Shareholder Meeting / Postal Ballot-Outcome of AGM", "datetime": "04-Sep-2026", "details": "Summary of the proceedings of the 41st Annual General Meeting of the Company held on Friday 04th September 2026.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate", "datetime": "04-Sep-2026", "details": "Re-Appointment of Shri. Dilip H. Bhuta (DIN 01357252) as Whole Time Director and CFO of the Company for the Period of 05 years from 01st April 2027 to 31st March 2032 Approved with requisite mejority by the shareholders at 41st AGM of the Company held today i.e. 04th September 2026.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Jenburkt Pharmaceuticals Ltd has declared <strong>207%</strong> dividend, ex-date: 28 Aug 26", "dt": "2026-08-28", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

3 Aug: Stock opens strong at Rs.1,090.75 (+1.29%) amid positive market sentiment

5 Aug: Sharp 5.64% rally to Rs.1,162.05 signalling bullish momentum

6 Aug: Mixed technical signals emerge despite price volatility

7 Aug: Quarterly results reveal margin pressures; stock falls 6.44% to Rs.1,062.50

Week Open

Rs.1,076.90

Read full news article

Jenburkt Pharmaceuticals Reports Decline in Quarterly Financial Performance Amid Margin Pressures

2026-08-07 11:00:07

Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable reversal in its recent financial trajectory. The company’s latest quarterly results for June 2026 reveal a marked decline in key performance metrics, signalling a shift from previously positive trends to a more challenging operating environment.

Read full news article

Jenburkt Pharmaceuticals Ltd. is Rated Hold by MarketsMOJO

2026-08-06 10:11:57

Jenburkt Pharmaceuticals Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 August 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Jenburkt Pharmaceuticals Ltd. Exhibits Shift to Mildly Bullish Momentum Amid Mixed Technical Signals

2026-08-06 08:00:14

Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a nuanced picture of the stock’s near-term prospects.

Read full news article

Jenburkt Pharmaceuticals Ltd.: Valuation Shift Signals Changing Market Sentiment

2026-08-06 08:00:10

Jenburkt Pharmaceuticals Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, prompting a downgrade in its Mojo Grade from Buy to Hold. This change reflects evolving market perceptions as the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios move into more expensive territory compared to historical and peer benchmarks.

Read full news article